AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions

DRUG: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
DRUG: Placebo to match CK-4021586

Sponsor

Cytokinetics